Lakefront Biotherapeutics (DE:GXEA)

FRANKFURT:GXEA

GXEA

Lakefront Biotherapeutics

RESEARCH TOOLSreports

Lakefront Biotherapeutics (GXEA) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

GXEA Analyst Ratings

Moderate Sell

0 Buy

1 Hold

1 Sell

Based on 2 analysts giving stock ratings to

Lakefront

Biotherapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

GXEA Stock 12 Month Forecast

Average Price Target

€21.60

▼(-11.49% Downside)

Based on 2 Wall Street analysts offering 12 month price targets for Lakefront Biotherapeutics in the last 3 months. The average price target is €21.60 with a high forecast of €24.19 and a low forecast of €19.01. The average price target represents a -11.49% change from the last price of €24.40.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"18":"€18","21":"€21","24":"€24","27":"€27","30":"€30"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":24.18931256,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€24.19</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.5976005,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€21.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.00588844,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€19.01</span>\n  </div></div>","useHTML":true}}],"tickPositions":[18,21,24,27,30],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.4,24.383793273846152,24.367586547692305,24.351379821538462,24.335173095384615,24.31896636923077,24.30275964307692,24.28655291692308,24.27034619076923,24.254139464615385,24.237932738461538,24.221726012307695,24.205519286153848,{"y":24.18931256,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.4,24.184430807692305,23.968861615384615,23.75329242307692,23.53772323076923,23.322154038461537,23.106584846153844,22.891015653846154,22.67544646153846,22.459877269230766,22.244308076923076,22.028738884615382,21.813169692307692,{"y":21.5976005,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.4,23.98506834153846,23.57013668307692,23.155205024615384,22.740273366153843,22.325341707692306,21.91041004923077,21.49547839076923,21.080546732307692,20.665615073846155,20.250683415384614,19.835751756923077,19.420820098461537,{"y":19.00588844,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":25,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":23.4,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":28.4,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.6,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":29.2,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":27,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.8,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":27.8,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":28.2,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":27.8,"date":1772323200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26,"date":1775001600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":23.8,"date":1777593600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":24.4,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€24.19

Average Price Target€21.60

Lowest Price Target€19.01

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Brian Abrahams

RBC Capital

€24.19

Hold

-0.86%

Downside

Reiterated

05/13/26

RBC Capital Sticks to Its Hold Rating for Lakefront Biotherapeutics (LKFT)

Judah Frommer

Morgan Stanley

€19.01

Sell

-22.11%

Downside

Reiterated

03/16/26

Morgan Stanley Keeps Their Sell Rating on Galapagos (GLPG)

Jason Gerberry

Bank of America Securities

€21.6→€24.19

Sell

-0.86%

Downside

Reiterated

11/06/25

Bank of America Securities Keeps Their Sell Rating on Galapagos (GLPG)

Faisal Khurshid

Jefferies

€25.05→€34.56

Buy

41.62%

Upside

Upgraded

10/22/25

Galapagos upgraded to Outperform from Market Perform at LeerinkGalapagos upgraded to Outperform from Market Perform at Leerink

Sean McCutcheon

Raymond James

―

Hold

―

Reiterated

07/24/25

Galapagos (GLPG) Receives a Hold from Raymond James

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Brian Abrahams

RBC Capital

€24.19

Hold

-0.86%

Downside

Reiterated

05/13/26

RBC Capital Sticks to Its Hold Rating for Lakefront Biotherapeutics (LKFT)

Judah Frommer

Morgan Stanley

€19.01

Sell

-22.11%

Downside

Reiterated

03/16/26

Morgan Stanley Keeps Their Sell Rating on Galapagos (GLPG)

Jason Gerberry

Bank of America Securities

€21.6→€24.19

Sell

-0.86%

Downside

Reiterated

11/06/25

Bank of America Securities Keeps Their Sell Rating on Galapagos (GLPG)

Faisal Khurshid

Jefferies

€25.05→€34.56

Buy

41.62%

Upside

Upgraded

10/22/25

Galapagos upgraded to Outperform from Market Perform at LeerinkGalapagos upgraded to Outperform from Market Perform at Leerink

Sean McCutcheon

Raymond James

―

Hold

―

Reiterated

07/24/25

Galapagos (GLPG) Receives a Hold from Raymond James

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

TRAXFirst Tracks Biotherapeutics Inc

EVMNEvommune, Inc.

MPLTMapLight Therapeutics, Inc.

MAZEMaze Therapeutics, Inc.

AAPGAscentage Pharma Group International Unsponsored ADR

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Lakefront Biotherapeutics

3 Months

Judah FrommerMorgan Stanley

Success Rate

7/14 ratings generated profit

Average Return

-0.96%

Copying Judah Frommer's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -0.96% per trade.

1 Year

Judah FrommerMorgan Stanley

Success Rate

10/14 ratings generated profit

Average Return

+1.85%

Copying Judah Frommer's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +1.85% per trade.

2 Years

Judah FrommerMorgan Stanley

Success Rate

9/14 ratings generated profit

Average Return

+3.66%

Copying Judah Frommer's trades and holding each position for 2 Years would result in 64.29% of your transactions generating a profit, with an average return of +3.66% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GXEA Analyst Recommendation Trends

Rating

Feb 26

Mar 26

Apr 26

May 26

Jun 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, GXEA has received 0 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. GXEA average Analyst price target in the past 3 months is 21.60.

Each month's total comprises the sum of three months' worth of ratings.

GXEA Financial Forecast

GXEA Earnings Forecast

Next quarter’s earnings estimate for GXEA is -€0.71 with a range of -€0.98 to -€0.43. The previous quarter’s EPS was €0.21. GXEA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year GXEA has Performed in-line its overall industry.

GXEA Sales Forecast

Next quarter’s sales forecast for GXEA is €5.32M with a range of €4.44M to €6.19M. The previous quarter’s sales results were €6.50M. GXEA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year GXEA has Performed in-line its overall industry.

GXEA Stock Forecast FAQ

What is DE:GXEA’s average 12-month price target, according to analysts?

Based on analyst ratings, Lakefront Biotherapeutics’s 12-month average price target is 21.60.

What is DE:GXEA’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for DE:GXEA, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Lakefront Biotherapeutics a Buy, Sell or Hold?

Lakefront Biotherapeutics has a consensus rating of Moderate Sell, which is based on 0 buy ratings, 1 hold ratings and 1 sell ratings.

What is Lakefront Biotherapeutics’s share price target?

The average share price target for Lakefront Biotherapeutics is 21.60. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €24.19 ,and the lowest forecast is €19.01. The average share price target represents -11.49% Decrease from the current price of €24.4.

What do analysts say about Lakefront Biotherapeutics?

Lakefront Biotherapeutics’s analyst rating consensus is a Moderate Sell. This is based on the ratings of 2 Wall Streets Analysts.

How can I buy shares of Lakefront Biotherapeutics?

To buy shares of DE:GXEA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Lakefront Biotherapeutics (GXEA) Stock Forecast & Price Target

GXEA Analyst Ratings

GXEA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Lakefront Biotherapeutics

GXEA Analyst Recommendation Trends

GXEA Financial Forecast

GXEA Earnings Forecast

GXEA Sales Forecast

GXEA Stock Forecast FAQ

Detailed List of Analyst Forecasts